Antonia 2017

Trial name or title	A global study to assess the effects of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non‐small cell lung cancer (PACIFIC)
Methods	Interventional RCT, Phrase III
Participants	Number of participants: 713 (May 2014 to Februray 2025 ) Number randomised: Experimental group (MEDI47361 immunotherapy): 476 Control group (Placebo): 237 Number evaluated: Experimental group: 473 Control group: 236 Diagnosis: patients with locally advanced unresectable stage III NSCLC Inclusion: The eligibility criteria are as follows: Age at least 18 years. Documented evidence of NSCLC (locally advanced, unresectable, Stage III) Patients must have received at least 2 cycles of platinum‐based chemotherapy concurrent with radiation therapy. World Health Organisation (WHO) Performance Status of 0 to 1. Estimated life expectancy of more than 12 weeks.
Interventions	Experimental group: MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . Control group: PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
Outcomes	Disease Free Survival, overall survival, adverse events
Starting date	May 7 2014
Contact information	scott.antonia@moffitt.org
Notes	This study is ongoing, but not recruiting participants